Dificid (fidaxomicin) is a brand-name drug prescribed for diarrhea caused by Clostridioides difficile (C. diff). It’s available as an oral tablet and oral liquid suspension. The cost of Dificid with ...
Dificid (fidaxomicin) is prescribed to treat diarrhea from Clostridioides difficile bacteria. Dificid’s cost may depend on your dosage and whether you have health insurance. It also may depend on the ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug ...
Will hospitals pay more for Optimer Pharmaceuticals' new antibiotic Dificid? That's the question, now that the FDA has given its blessing to the drug, which is the first new treatment in 25 years for ...
NEW YORK (AP) -- Shares of Optimer Pharmaceuticals tumbled 6 percent Tuesday as Wall Street weighed in on the company's marketing strategy and sales of its antibacterial drug Dificid. THE SPARK: ...
TORONTO, July 5, 2012 /CNW/ - Optimer Pharmaceuticals Canada, Inc. announced today the approval of DIFICID (fidaxomicin) by Health Canada for the treatment of Clostridium difficile infection (CDI) in ...
The U.S. Food and Drug Administration approved Merck's (MRK-0.29%) Dificid drug for children aged 6 months and older who have diarrhea caused by a specific bacterial infection called Clostridioides ...
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Therapeutic Goods Administration, the Australian regulatory body for therapeutic goods such as medicines, has approved DIFICID® ...
Scientists have determined the molecular target and mechanism of the antibacterial drug fidaxomicin (trade name Dificid). Fidaxomicin was approved in 2011 for treatment of the CDC 'urgent threat' ...
Cubist Pharmaceuticals (CBST +0.00%) is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute ...
NEW YORK -- Shares of Optimer Pharmaceuticals tumbled 6 percent Tuesday as Wall Street weighed in on the company's marketing strategy and sales of its antibacterial drug Dificid. THE SPARK: Optimer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results